Lohmann managing director Bruno Kaesler said “With the high level of know-how and the focused result-orientation of the scientists here, we are committed to converting these research products into commercial success.
“The range of new vaccines in development and the innovative technology involved represent a great market potential.”
The German company intends to invest at least US$12.82mn in a factory in
Work on the factory should begin in the second half of the year and take a year or two to build and another four years will be needed to get approvals to sell products in
“
Alain Charles Publishing, University House, 11-13 Lower Grosvenor Place, London, SW1W 0EX, UK
T: +44 20 7834 7676, F: +44 20 7973 0076, W: www.alaincharles.com